Promethera Biosciences SA NV
www.promethera.com
Latest From Promethera Biosciences SA NV
Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Venture Funding Deals: Takeda's Phathom Raises $140m In Crossover Round For GERD Program
AgomAb, CinCor and Confo Therapeutics secure Series A financing, while AlloVir closes a $121m Series B and more venture financing in April and May.
Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
Finance Watch: A One-Time Treatment For Heart Disease? Verve Raises $58.5m To Give It A Try
Private Company Edition: With academic muscle, Google cash and nanoparticles, and various CRISPR licenses, Verve will develop gene-editing therapies for coronary heart disease prevention. Also, Vividion raises an $82m series B and two Belgian companies bring in $77.8m in VC cash.
Company Information
- Industry
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Pharmaceuticals
- Therapeutic Areas
- Hepatic (Liver)
- Alias(es)
- Promethera Biosciences
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Benelux
-
Belgium
-
Belgium
-
Benelux
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Promethera Biosciences SA NV
- Senior Management
-
John Tchelingerian, PhD, Pres. & CEO
Mutsuki Takano, CFO
Etienne Sokal, MD, PhD, CMO & CSO
Henrik L Luessen, PhD, CBO - Contact Info
-
Promethera Biosciences SA NV
Phone: (32) (0)10 39 43 00
Rue Granbonpré, 11
Watson & Crick
Mont-Saint-Guibert, B-1435
Belgium
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice